CRISPR Therapeutics (CRSP)

• Market cap: $4.11B
• 1 day: -5.00%
• 5 days: 3.68%
• 1 month: 15.42%
• 3 months: 3.50%
• 6 months: -4.16%
• Year to date: 15.64%
• 1 year: -41.86%
• 5 years: -9.65%
• 10 years: 240.03%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Employees: 393

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

5.33% more ownership

Funds ownership: 70.24% [Q3] → 75.57% (+5.33%) [Q4]

3% less repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 116

6% less funds holding

Funds holding: 409 [Q3] → 385 (-24) [Q4]

10% less capital invested

Capital invested by funds: $2.81B [Q3] → $2.54B (-$268M) [Q4]

11% less first-time investments, than exits

New positions opened: 59 | Existing positions closed: 66

11% less call options, than puts

Call options by funds: $81.6M | Put options by funds: $91.6M

20% less funds holding in top 10

Funds holding in top 10: 5 [Q3] → 4 (-1) [Q4]

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $32 33% downside
• Avg. target: $73 52% upside
• High target: $120 150% upside

13 analyst ratings

• positive: 8 62%
• neutral: 4 31%
• negative: 1 8%

Citigroup Yigal Nochomovitz 33% 1-year accuracy 14 / 43 met price target	71% upside $82	Buy Maintained	18 Feb 2025
Morgan Stanley Terence Flynn 50% 1-year accuracy 9 / 18 met price target	33% downside $32	Underweight Maintained	14 Feb 2025
Evercore ISI Group Liisa Bayko 71% 1-year accuracy 10 / 14 met price target	107% upside $99	Outperform Upgraded	14 Feb 2025
Goldman Sachs Salveen Richter 27% 1-year accuracy 4 / 15 met price target	19% upside $57	Neutral Maintained	13 Feb 2025
JMP Securities Silvan Tuerkcan 32% 1-year accuracy 18 / 56 met price target	80% upside $86	Market Outperform Reiterated	13 Feb 2025